세계의 유아성 경련 치료제 시장 규모, 점유율, 성장 분석, 치료제별, 유형별, 형태별, 투여 경로별, 최종사용자별, 유통 채널별, 지역별 - 산업 예측(2025-2032년)
Infantile Spasms Therapeutics Market Size, Share, and Growth Analysis, By Treatment, By Type, By Dosage, By Route of Administration, By End User, By Distribution Channel, By Region - Industry Forecast 2025-2032
유아성 경련 치료제 세계 시장 규모는 2023년 1억 4,000만 달러, 2024년 1억 4,924만 달러에서 2032년에는 2억 4,885만 달러로 성장하고, 예측 기간(2025-2032년)의 CAGR은 6.6%를 나타낼 전망입니다.
시장 개발 인사이트에 따르면, 영아 경련 치료제에 대한 세계 수요는 선진국과 신흥 시장 모두에서 유병률이 증가하고 있는 추세에 힘입어 성장하고 있습니다. 소아과 의사의 인식 개선과 연구개발에 대한 막대한 투자가 매출 성장을 견인하고 있으며, 약물 제제의 발전과 소아신경학 서비스의 확대가 이러한 치료법에 대한 접근성을 향상시키고 있습니다. 첨단 뇌파, MRI, 유전자 시퀀싱과 같은 혁신적인 도구가 조기 진단을 촉진하고 있습니다. 정부 의료 프로그램 및 비영리 단체의 지원으로 희귀 소아 신경질환에 대한 인식과 자금이 더욱 증가하고 있습니다. 그러나 높은 치료비, 숙련된 전문의 부족, 기존 치료제의 부작용 가능성, 후진국에서의 진단 부족 등의 문제는 향후 시장 매출에 걸림돌이 될 수 있습니다.
목차
서론
조사 방법
- 정보 조달
- 2차와 1차 데이터 방법
- 시장 규모 예측
- 시장 전제조건과 제한
주요 요약
- 세계 시장 전망
- 공급과 수요 동향 분석
- 부문별 기회 분석
시장 역학과 전망
- 시장 개요
- 시장 규모
- 시장 역학
- Porter의 Five Forces 분석
주요 시장 인사이트
- 중요 성공 요인
- 경쟁 정도
- 주요 투자 기회
- 시장 생태계
- 시장의 매력 지수(2024년)
- PESTEL 분석
- 거시경제 지표
- 밸류체인 분석
- 가격 분석
- 사례 연구
유아성 경련 치료제 시장 규모 : 치료제별&CAGR(2025-2032)
유아성 경련 치료제 시장 규모 : 유형별&CAGR(2025-2032)
- 시장 개요
- 비가바트린
- 부신피질 자극 호르몬
- 3상
유아성 경련 치료제 시장 규모 : 형태별&CAGR(2025-2032)
유아성 경련 치료제 시장 규모 : 투여 경로별&CAGR(2025-2032)
유아성 경련 치료제 시장 규모 : 최종사용자별&CAGR(2025-2032)
유아성 경련 치료제 시장 규모 : 유통 채널별&CAGR(2025-2032)
유아성 경련 치료제 시장 규모 : 지역별&CAGR(2025-2032)
- 북미
- 유럽
- 아시아태평양
- 라틴아메리카
- 중동 및 아프리카
- GCC 국가
- 남아프리카공화국
- 기타 중동 및 아프리카
경쟁 정보
- 주요 5개사 비교
- 주요 기업의 시장 포지셔닝(2024년)
- 주요 시장 기업이 채택한 전략
- 최근 시장 동향
- 기업의 시장 점유율 분석(2024년)
- 주요 기업 개요
- 기업 상세
- 제품 포트폴리오 분석
- 기업 부문별 점유율 분석
- 매출 전년대비 비교(2022-2024년)
주요 기업 개요
- Amneal Pharmaceuticals LLC(U.S.)
- Cipla(India)
- Endo, Inc.(U.S.)
- H. Lundbeck A/S(Denmark)
- Hetero(India)
- Intas Pharmaceuticals Ltd.(India)
- Jazz Pharmaceuticals, Inc.(Ireland)
- Mallinckrodt(Ireland)
- MSN Laboratories(India)
- Ovid Therapeutics(U.S.)
- SGPharma Pvt. Ltd.(India)
- Teva Pharmaceutical Industries Ltd.(Israel)
- Zydus Group(India)
- Merz Therapeutics(U.S.)
- Ionis Pharmaceuticals(U.S.)
- Sun Pharmaceutical Industries Ltd.(India)
- Dr. Reddy's Laboratories Ltd.(India)
- Eisai Co., Ltd.(Japan)
결론과 제안
LSH
Global Infantile Spasms Therapeutics Market size was valued at USD 140.0 million in 2023 and is poised to grow from USD 149.24 million in 2024 to USD 248.85 million by 2032, growing at a CAGR of 6.6% during the forecast period (2025-2032).
Market insights indicate a rising global demand for infantile spasms therapeutics, driven by an increasing prevalence of the condition in both developed and developing regions. Enhanced awareness among pediatricians and significant investments in R&D are propelling revenue growth, while advancements in drug formulations and the expansion of pediatric neurology services improve access to these therapies. Innovative tools such as advanced EEG, MRI, and genetic sequencing are facilitating earlier diagnoses. Support from government healthcare programs and nonprofit organizations is further amplifying awareness and funding for rare pediatric neurological disorders. However, challenges such as high treatment costs, a scarcity of trained specialists, potential side effects of existing treatments, and underdiagnosis in less developed areas may hinder market sales in the future.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Infantile Spasms Therapeutics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Infantile Spasms Therapeutics Market Segments Analysis
Global Infantile Spasms Therapeutics Market is segmented by Treatment, Type, Dosage, Route of Administration, End User, Distribution Channel and region. Based on Treatment, the market is segmented into Anticonvulsants, Corticosteroids and Others. Based on Type, the market is segmented into Vigabatrin, Adrenocorticotropic Hormone and Phase III. Based on Dosage, the market is segmented into Solid and Liquid. Based on Route of Administration, the market is segmented into Oral, Parenteral and Others. Based on End User, the market is segmented into Clinic, Hospital and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Retail Pharmacy and Online Pharmacy. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Global Infantile Spasms Therapeutics Market
The increasing awareness among the medical community regarding infantile spasms has significantly improved the speed of diagnosis and treatment. Pediatricians and general practitioners are now more knowledgeable about the condition's symptoms and the critical need for prompt intervention, resulting in quicker referrals to specialists for suspected cases. This heightened clinical awareness has accelerated therapeutic responses, minimizing long-term neurodevelopmental impairment and promoting a greater reliance on therapeutics designed for infantile spasms. Consequently, this trend is driving growth in the global market for infantile spasms therapeutics, as more healthcare providers prioritize timely and effective care for affected infants.
Restraints in the Global Infantile Spasms Therapeutics Market
The Global Infantile Spasms Therapeutics market faces notable challenges due to the substantial side effects associated with treatments such as ACTH and vigabatrin. Adverse effects including adrenal suppression, vision loss, and immune suppression often create hesitation among healthcare providers and parents regarding the initiation of therapy. This apprehension can result in premature discontinuation or outright avoidance of treatment, especially in borderline cases. Additionally, the lack of safer long-term alternative therapies exacerbates these concerns, impacting overall treatment compliance and limiting the market's growth potential. Hence, these factors represent a significant restraint within the sector.
Market Trends of the Global Infantile Spasms Therapeutics Market
The Global Infantile Spasms Therapeutics market is witnessing a significant shift towards precision medicine and genetic profiling, driven by advances in molecular diagnostics. This trend underscores the importance of personalized treatment strategies, with genetic testing and next-generation sequencing playing crucial roles in identifying the underlying causes of infantile spasms. As these technologies become more affordable and accessible, pharmaceutical companies are increasingly investing in mutation-targeted therapies, enhancing the effectiveness of treatments. This strategic focus on tailored approaches is expected to shape the future of the market, leading to improved patient outcomes and fostering innovation in therapeutic options for infantile spasms.
Table of Contents
Introduction
- Objectives of the Study
- Scope of the Report
- Definitions
Research Methodology
- Information Procurement
- Secondary & Primary Data Methods
- Market Size Estimation
- Market Assumptions & Limitations
Executive Summary
- Global Market Outlook
- Supply & Demand Trend Analysis
- Segmental Opportunity Analysis
Market Dynamics & Outlook
- Market Overview
- Market Size
- Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
- Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers
Key Market Insights
- Key Success Factors
- Degree of Competition
- Top Investment Pockets
- Market Ecosystem
- Market Attractiveness Index, 2024
- PESTEL Analysis
- Macro-Economic Indicators
- Value Chain Analysis
- Pricing Analysis
- Case Studies
Global Infantile Spasms Therapeutics Market Size by Treatment & CAGR (2025-2032)
- Market Overview
- Anticonvulsants
- Corticosteroids
- Others
Global Infantile Spasms Therapeutics Market Size by Type & CAGR (2025-2032)
- Market Overview
- Vigabatrin
- Adrenocorticotropic Hormone
- Phase III
Global Infantile Spasms Therapeutics Market Size by Dosage & CAGR (2025-2032)
- Market Overview
- Solid
- Liquid
Global Infantile Spasms Therapeutics Market Size by Route of Administration & CAGR (2025-2032)
- Market Overview
- Oral
- Parenteral
- Others
Global Infantile Spasms Therapeutics Market Size by End User & CAGR (2025-2032)
- Market Overview
- Clinic
- Hospital
- Others
Global Infantile Spasms Therapeutics Market Size by Distribution Channel & CAGR (2025-2032)
- Market Overview
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
Global Infantile Spasms Therapeutics Market Size & CAGR (2025-2032)
- North America (Treatment, Type, Dosage, Route of Administration, End User, Distribution Channel)
- Europe (Treatment, Type, Dosage, Route of Administration, End User, Distribution Channel)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
- Asia Pacific (Treatment, Type, Dosage, Route of Administration, End User, Distribution Channel)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America (Treatment, Type, Dosage, Route of Administration, End User, Distribution Channel)
- Brazil
- Rest of Latin America
- Middle East & Africa (Treatment, Type, Dosage, Route of Administration, End User, Distribution Channel)
- GCC Countries
- South Africa
- Rest of Middle East & Africa
Competitive Intelligence
- Top 5 Player Comparison
- Market Positioning of Key Players, 2024
- Strategies Adopted by Key Market Players
- Recent Developments in the Market
- Company Market Share Analysis, 2024
- Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2022-2024)
Key Company Profiles
- Amneal Pharmaceuticals LLC (U.S.)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Cipla (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Endo, Inc. (U.S.)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- H. Lundbeck A/S (Denmark)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Hetero (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Intas Pharmaceuticals Ltd. (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Jazz Pharmaceuticals, Inc. (Ireland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Mallinckrodt (Ireland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- MSN Laboratories (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Ovid Therapeutics (U.S.)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- SGPharma Pvt. Ltd. (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Teva Pharmaceutical Industries Ltd. (Israel)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Zydus Group (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Merz Therapeutics (U.S.)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Ionis Pharmaceuticals (U.S.)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sun Pharmaceutical Industries Ltd. (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Dr. Reddy's Laboratories Ltd. (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Eisai Co., Ltd. (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Conclusion & Recommendations
